Analysts predict that Exelixis, Inc. (NASDAQ:EXEL) will post sales of $117.71 million for the current quarter, according to Zacks. Six analysts have issued estimates for Exelixis’ earnings. The highest sales estimate is $133.73 million and the lowest is $108.10 million. Exelixis posted sales of $77.58 million during the same quarter last year, which suggests a positive year-over-year growth rate of 51.7%. The firm is expected to report its next earnings report on Monday, February 26th.

On average, analysts expect that Exelixis will report full-year sales of $117.71 million for the current fiscal year, with estimates ranging from $440.40 million to $466.03 million. For the next year, analysts anticipate that the company will post sales of $599.11 million per share, with estimates ranging from $511.30 million to $762.02 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Exelixis.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The firm had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. During the same period last year, the business earned ($0.04) earnings per share. Exelixis’s revenue was up 145.2% compared to the same quarter last year.

Several research firms recently issued reports on EXEL. Needham & Company LLC raised their price objective on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research report on Monday, September 25th. BidaskClub cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Royal Bank Of Canada lifted their price target on shares of Exelixis from $33.00 to $39.00 and gave the company an “outperform” rating in a research report on Tuesday, October 17th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $26.00 price target on shares of Exelixis in a research report on Tuesday, October 17th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Exelixis currently has a consensus rating of “Buy” and a consensus target price of $31.38.

Exelixis (NASDAQ:EXEL) traded down $0.50 during trading on Monday, reaching $26.61. 1,150,499 shares of the company traded hands, compared to its average volume of 4,090,856. Exelixis has a 52-week low of $14.22 and a 52-week high of $32.50. The firm has a market capitalization of $8,020.58, a PE ratio of 53.16, a P/E/G ratio of 1.22 and a beta of 1.89.

In related news, CFO Christopher J. Senner sold 100,000 shares of Exelixis stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $26.79, for a total value of $2,679,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Morrissey sold 300,000 shares of Exelixis stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $26.90, for a total transaction of $8,070,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 970,152 shares of company stock valued at $25,923,457. Company insiders own 5.10% of the company’s stock.

A number of institutional investors have recently modified their holdings of EXEL. Mark Sheptoff Financial Planning LLC purchased a new position in Exelixis in the third quarter worth approximately $120,000. Fisher Asset Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $213,000. Wetherby Asset Management Inc. purchased a new stake in shares of Exelixis during the 2nd quarter worth approximately $218,000. Caxton Associates LP purchased a new stake in shares of Exelixis during the 2nd quarter worth approximately $227,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $236,000. Institutional investors own 81.19% of the company’s stock.

WARNING: “Exelixis, Inc. (EXEL) Expected to Post Quarterly Sales of $117.71 Million” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/11/exelixis-inc-exel-expected-to-post-quarterly-sales-of-117-71-million.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.